Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 12
2014 33
2015 30
2016 41
2017 55
2018 48
2019 52
2020 74
2021 98
2022 69
2023 40
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31262919

450 results

Results by year

Filters applied: . Clear all
Page 1
Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Urol Oncol. 2017 Jun;35(6):432-437. doi: 10.1016/j.urolonc.2017.01.006. Epub 2017 Feb 8. Urol Oncol. 2017. PMID: 28188090
Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Miyake H, et al. Clin Genitourin Cancer. 2018 Jun;16(3):219-225. doi: 10.1016/j.clgc.2017.11.007. Epub 2017 Dec 6. Clin Genitourin Cancer. 2018. PMID: 29274813
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM. Badrising S, et al. Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30. Cancer. 2014. PMID: 24382803 Free article.
450 results